|
1.
Evaluation of residual CD34+/Ph+ stem cells in chronic myeloid leukemia
patients in complete cytogenetic response during front line nilotinib
therapy Defina M,
Ippoliti M, Abruzzese E, Castagnetti F, Tiribelli M, Rosti G, Breccia M,
Trawinska MM, Crupi R, Aprile L, Salvucci M, Baratè C, Gozzini A,
Rondoni M, Zaccaria A, Alimena G, Santini V, Specchia G, Fanin R,
Gozzetti A, Baccarani M, Lauria F, Bocchia M. Haematologica.
43° Congress of the Italian Society of Hematology. 16-19 October 2011,
Naples, Italy.
2.
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes.
Preliminary Results of a Multicenter Phase II Study. Carla Filì, Carlo
Finelli, Marco Gobbi, Giovanni Martinelli, Ilaria Iacobucci, Emanuela
Ottaviani, Lucio Cocco, Matilde Follo, Anna Candoni, Erika Simeone,
Maurizio Miglino, Francesco Lauria, Monica Bocchia, Marzia Defina,
Cristina Clissa, Francesco Lanza, Antonio Curti, Stefania Paolini,
PierAngelo Spedini, Cristina Skert, Cesare Bergonzi, Michele Malagola,
Annalisa Peli, Alessandro Turra, Federica Cattina, Chiara Colombi, and
Domenico Russo. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:
4029.
3.
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia
Patients In Complete Cytogenetic Response during First Line Nilotinib
Therapy.
Monica Bocchia, Marzia Defina, Micaela Ippoliti, Elisabetta
Abruzzese, Fausto Castagnetti, Mario Tiribelli, Gianantonio Rosti,
Massimo Breccia, Malgorzata Monika Trawinska, Rosaria Crupi, Lara
Aprile, Marzia Salvucci, Claudia Baratè, Antonella Gozzini, Michela
Rondoni, Alfonso Zaccaria, Giuliana Alimena, Valeria Santini, Giorgina
Specchia, Renato Fanin, Alessandro Gozzetti, and Francesco Lauri. Blood
(ASH Annual Meeting Abstracts), Nov 2010; 116: 3413.
4.
Long-lasting p210 peptide vaccine treatment in chronic myeloid leukemia
patients: safety profile and clinical results.
Defina M.
Ippoliti M, Gozzetti A. Crupi R, Aprile L, Tassi M, Rondoni M, Lauria F,
Bocchia M. Haematologica.
15th Congress of the European Hematology Association. Barcellona, Spain,
June 10-13, 2010
5.
Identification of a novel p190-derived breakpoint peptide suitable for
peptide vaccine therapeutic approach in Ph+ acute lymphoblastic
leukemia patients.
Ippoliti M, Defina
M, Aprile L, Gozzetti A, Crupi R, Tassi M, Rondoni M, Lauria F,
Bocchia M. XI National SIES meeting.
Turin, Italy, October 6-8, 2010.
6.
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients
with Molecular Minimal Residual Disease During Imatinib: Interim
Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.
Monica Bocchia, Marzia Defina,
Micaela Ippoliti, Marilina Amabile, Massimo Breccia, Francesco Iuliano,
Marco Vignetti, Gabriele Gugliotta, Antonella Russo Rossi, Giuliana
Alimena, Lara Aprile, Gianluca Gaidano, Paolo Nicoli, Malgorzata Monika
Trawinska, Renato Bassan, Diamante Turri, Laura Cannella, Luigia
Luciano, Alessandro Gozzetti, Michela Rondoni, Gianantonio Rosti,
Giovanni Martinelli, Michele Baccarani, and Francesco Lauria. Blood (ASH
Annual Meeting Abstracts), Nov 2009; 114: 648.
7.
Long Term Follow up Analysis Following Front Line Therapy with
Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary
Immune Thrombocytopenia.
Francesco Zaja, Michele Baccarani, Patrizio Mazza, Nicola Vianelli,
Monica Bocchia, Marzia Defina, Luigi Gugliotta, Alessia Tienghi,
Sergio Amadori, Selenia Campagna, Felicetto Ferrara, Mariacarla De
Simone, Alfonso Zaccaria, Anna Lia Molinari, Emanuele Angelucci, Emilio
Usala, Silvia Cantoni, Antonella Fornaro, Giuseppe Visani, Rita Rizzi,
Valerio De Stefano, Francesco Casulli, Marta Battista, Miriam Isola,
Franca Soldano, and Renato Fanin. Blood (ASH Annual Meeting Abstracts),
Nov 2009; 114: 2415.
8.
Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide)
as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients
Younger Than 65 Ys: Response and Follow-up of 84 Patients.
Michela Rondoni, Michele Malagola, Stefania Paolini, Marzia Defina,
Pier Paolo Piccaluga, Lara Aprile, Cristina Papayannidis, Nicoletta
Testoni, Rosaria Crupi, Alessandro Gozzetti, Monica Tozzi, Giuseppe
Marotta, Francesca Toraldo, Domenico Russo, Monica Bocchia, Michele
Baccarani, Giovanni Martinelli, and Francesco Lauria
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4147.
9.
Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly
Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.
Carla Filí, Marco Gobbi, Giovanni Martinelli, Carlo Finelli, Ilaria
Iacobucci, Emanuela Ottaviani, Lucio Cocco, Matilde Y Follo, Anna
Candoni, Erica Simeone, Maurizio Miglino, Francesco Lauria, Monica
Bocchia, Marzia Defina, Cristina Clissa, Cristina Skert, Cesare
Bergonzi, Michele Malagola, Aldo M. Roccaro, Annalisa Peli, Alessandro
Turra, Chiara Colombi, and Domenico Russo
Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4851
10.
Response to Dasatinib in patients with sistemi mastocytosis with D816V
kit mutation: 9 italian cases.
Rondoni M, Paolini S, Colarossi S, Fabbri A, Pregno P, Piccaluga PP,
Galimberti S, Baratè C, Papayannidis C, Defina M, Soverini S,
Lauria F, Baccarani M, Martinelli G. Haematologica.
42° Congress of the Italian Society of Hematology. 18-21 October 2009,
Milan, Italy.
11. Low
dose Rituxiamb as salvage therapy in adult patients with primary immune
thrombocytopenia.
Zaja F,
Battista ML, Defina M, Vianelli N, Palmieri S, Bocchia M, Medeot
M, Volpetti S, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R. Haematologica.
42° Congress of the Italian Society of Hematology. 18-21 October 2009,
Milan, Italy.
12.
Bortezomib, pegylate liposomal doxorubicin and dexamethasone (B-PLD-D)
as therapy for elderly patients with relapsed refractory multiple
myeloma: a weekly bortezomib infusion schedule reduces toxicities
maintaining the same efficacy.
Gozzetti A, Fabbri A,
Oliva S, Marchini E, Bocchia M, Defina M, Lauria F. Haematologica.
42° Congress of the Italian Society of Hematology. 18-21 October 2009,
Milan, Italy.
13.
Clinical and biological effects of 5-azacitidine five days/monthly
schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic patients.
Filì C,
Bergonzi C, Skert C, Malagola M, Roccaro AM, Peli A, Turra A, Colombi C,
Cattina F, Martinelli G, Finelli C,Clissa C, Iacobucci I, Ottaviani E,
Cocco L, Follo MY, Candoni A, Simeone E, Gobbi M, Miglino M, Lauria F,
Bocchia M, Defina M, Russo D. Haematologica.
42° Congress of the Italian Society of Hematology. 18-21 October 2009,
Milan, Italy.
|